JP2025508896A - 癌のためのｃｔｐｓ１阻害剤とｂｃｌ２阻害剤の組合せ - Google Patents

癌のためのｃｔｐｓ１阻害剤とｂｃｌ２阻害剤の組合せ Download PDF

Info

Publication number
JP2025508896A
JP2025508896A JP2024550789A JP2024550789A JP2025508896A JP 2025508896 A JP2025508896 A JP 2025508896A JP 2024550789 A JP2024550789 A JP 2024550789A JP 2024550789 A JP2024550789 A JP 2024550789A JP 2025508896 A JP2025508896 A JP 2025508896A
Authority
JP
Japan
Prior art keywords
cyclopropanesulfonamido
inhibitor
thiazol
ctps1
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508896A5 (https=
Inventor
ビアー フィリップ
シロン デービッド
パーカー アンドリュー
ペラ‐ディセニンク キャサリン
Original Assignee
ステップ ファーマ エス．エー．エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステップ ファーマ エス．エー．エス filed Critical ステップ ファーマ エス．エー．エス
Publication of JP2025508896A publication Critical patent/JP2025508896A/ja
Publication of JP2025508896A5 publication Critical patent/JP2025508896A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024550789A 2022-03-01 2023-03-01 癌のためのｃｔｐｓ１阻害剤とｂｃｌ２阻害剤の組合せ Pending JP2025508896A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22305225.9 2022-03-01
EP22305225 2022-03-01
EP22306429.6 2022-09-27
EP22306429 2022-09-27
PCT/EP2023/055217 WO2023166076A1 (en) 2022-03-01 2023-03-01 Combinations of ctps1 and bcl2 inhibitors for cancer

Publications (2)

Publication Number Publication Date
JP2025508896A true JP2025508896A (ja) 2025-04-10
JP2025508896A5 JP2025508896A5 (https=) 2026-03-09

Family

ID=85384465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550789A Pending JP2025508896A (ja) 2022-03-01 2023-03-01 癌のためのｃｔｐｓ１阻害剤とｂｃｌ２阻害剤の組合せ

Country Status (6)

Country Link
US (1) US20250177394A1 (https=)
EP (1) EP4486347A1 (https=)
JP (1) JP2025508896A (https=)
AU (1) AU2023228045A1 (https=)
CA (1) CA3244038A1 (https=)
WO (1) WO2023166076A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
IL288508B2 (en) 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
WO2024133730A1 (en) * 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717465B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
MX2020009887A (es) 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
IL288508B2 (en) 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
EP3980410B1 (en) 2019-06-04 2025-02-19 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
EP4041715A1 (en) 2019-09-20 2022-08-17 Step Pharma S.A.S. Sulfonamide inhibitors as ctps 1 inhibitors
WO2021053402A2 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Compounds
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4486347A1 (en) 2025-01-08
AU2023228045A1 (en) 2024-08-15
CA3244038A1 (en) 2023-09-07
US20250177394A1 (en) 2025-06-05
WO2023166076A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
JP2025508896A (ja) 癌のためのｃｔｐｓ１阻害剤とｂｃｌ２阻害剤の組合せ
WO2023166078A1 (en) Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
JP7428692B2 (ja) Ｃｔｐｓ１阻害剤としてのアミノピリミジン誘導体
TWI651303B (zh) 經取代苯化合物
US9173893B2 (en) Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
JP5340931B2 (ja) 骨髄増殖性疾患治療用ｊａｋ阻害剤
WO2023166077A1 (en) Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2024133721A1 (en) Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
WO2020245665A1 (en) N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
WO2019106156A1 (en) Compounds
JP2025542211A (ja) Ｃｔｐｓ２欠損癌の治療において使用するためのｃｔｐｓ１阻害剤
WO2019106146A1 (en) Compounds
WO2023166080A1 (en) Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
Petrelli et al. Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade
JP2024533121A (ja) 混合系統キナーゼ阻害薬および使用方法
JPWO2007148835A1 (ja) 抗ガン剤耐性克服剤
JP2023539754A (ja) Ｌｚｋ標的化分解剤および使用方法
JP7005508B2 (ja) ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体
CN118804752A (zh) Ctps1和bcl2抑制剂联合治疗癌症
TW201504239A (zh) 蛋白酪氨酸激酶抑制劑及其應用
JP7443252B2 (ja) Ｊａｋ３選択的阻害剤
He Unraveling PI5P4K’s Immunomodulatory Role in Lung Cancer Tumor Microenvironment⎯ A Druggable Target to Promote Anti-Tumor Immunity
WO2026027753A1 (en) Ctps1 inhibitors for the treatment of myeloproliferative neoplasms
HK40104785A (en) Alkynyl nucleoside analogs as inhibitors of human rhinovirus
Petrelli et al. Novel inhibitors of inosine monophosphate dehydrogenase as potential anti-cancer drugs: A patent review (2002-2014)

Legal Events

Date Code Title Description
RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260225